Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
World Clinical Trials Racial Representation Data Study 2022 Featuring Novartis, GSK, Pfizer, Johnson & Johnson, AstraZeneca, F. Hoffmann-La Roche, Eli Lilly, Merck & Co, AbbVie, & Bayer | ||
By: PR Newswire Association LLC. - 23 Nov 2022 | Back to overview list |
|
DUBLIN, Nov. 23, 2022 /PRNewswire/ -- The "Clinical Trials - The Importance of Diversity in Clinical Trials" report has been added to ResearchAndMarkets.com's offering. This report provides an analysis of clinical trial racial representation data and evaluates racial demographics across a number of clinical trials sectors to highlight the level of diversity. The clinical trials data used for these analyses was extracted from the publisher's Clinical Trials Database, captured on June 16 and July 19, 2022. The data primarily includes clinical trials initiated from January 1, 2013 to June 16, 2022. Disclosed racial representation data has been analyzed by location, by year, phase, therapy area, sponsor type, top industry sponsors, pivotal study status, single country and multinational trials, decentralized trials, and CRO involvement. Additional analysis on obstacles in the recruitment of diverse subject populations in clinical trials and steps which can be taken to increase diversity have also been included. Reasons to Buy
Key Topics Covered:
Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/r/7qavq9 Media Contact: Research and Markets
For E.S.T Office Hours Call +1-917-300-0470
U.S. Fax: 646-607-1907 Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg
SOURCE Research and Markets |
||
|
||
Copyright 2022 PR Newswire Association LLC. | Back to overview list |